BRAIN and NERVE－神経研究の進歩76巻5号

2024年05月発行

増大特集 末梢神経・筋肉の自己免疫性・炎症性疾患ハンドブック

第2章　疾患各論

ランバート・イートン筋無力症候群

著者： 松尾秀徳¹

所属機関： ¹国立病院機構長崎病院脳神経内科

ページ範囲：P.630 - P.634

文献概要

ランバート・イートン筋無力症候群は，近位筋力低下，腱反射の低下，および自律神経障害を呈する神経筋接合部疾患で，50〜60％に小細胞肺癌を合併する。P/Q型電位依存性カルシウムチャネルに対する自己抗体が病態に関与している。重症筋無力症／ランバート・イートン筋無力症候群診療ガイドライン2022では，臨床症状，特徴的な電気生理学的所見および病原性自己抗体による診断基準および治療アルゴリズムが示されている。

参考文献

1）Anderson HJ, Churchill-Davidson HC, Richard AT: Bronchial neoplasm with myasthenia. Prolonged apnea after administration of succinylcholine. Lancet 265: 1291-1293, 1953

2）Henson RA, Russel DS, Wilkinson M: Carcinomatous neuropathy and myopathy a clinical and pathological study. Brain 77: 82-121, 1954

3）Lambert EH, Eaton LM, Rooke ED: Defect of neuromuscular conduction associated with malignant neoplasms. Am J Physiol 187: 612-613, 1956

4）Lang B, Newsom-Davis J, Wray D, Vincent A, Murray N: Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet 2: 224-226, 1981

5）Pumplin DW, Reese TS, Llinas R: Are the presynaptic membrane particles the calcium channels? Proc Natl Acad Sci U S A 78: 7210-7213, 1981

6）Fukunaga H, Engel AG, Lang B, Newsom-Davis J, Vincent A: Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc Natl Acad Sci U S A 80: 7630-7640, 1983

7）Motomura M, Johnston I, Lang B, Vincent A, Newsom-Davis J: An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 58: 85-87, 1995

8）Fukuda T, Motomura M, Nakao Y, Shiraishi H, Yoshimura T, et al: Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome. Ann Neurol 53: 21-28, 2003

9）Nakatani Y, Tanaka N, Enami T, Minami S, Okazaki T, et al: Lambert-Eaton myasthenic syndrome caused by nivolumab in a patient with squamous cell lung cancer. Case Rep Neurol 10: 346-352, 2018

10）Shimizu F, Takeshita Y, Sano Y, Hamamoto Y, Shiraishi H, et al: GRP78 antibodies damage the blood-brain barrier and relate to cerebellar degeneration in Lambert-Eaton myasthenic syndrome. Brain 142: 2253-2264, 2019

11）Wirtz PW, van Dijk JG, van Doorn PA, Van Engelen BG, van der Kooi AJ, et al: The epidemiology of the Lambert-Eaton myasthenic syndrome in the Netherlands. Neurology 63: 397-398, 2004

12）Abenroth DC, Smith AG, Greenlee JE, Austin SD, Clardy SL: Lambert-Eaton myasthenic syndrome: epidemiology and therapeutic response in the national veterans affairs population. Muscle Nerve 56: 421-426, 2017

13）Yoshikawa H, Adachi Y, Nakamura Y, Kuriyama N, Murai H, et al: Nationwide survey of Lambert-Eaton myasthenic syndrome in Japan. BMJ Neurol Open 4: e000291, 2022［doi: 10.1136/bmjno-2022-000291］

14）Nakao YK, Motomura M, Fukudome T, Fukuda T, Shiraishi H, et al: Seronegative Lambert-Eaton myasthenic syndrome: study of 110 Japanese patients. Neurology 59: 1773-1775, 2002

15）O'Neill JH, Murray NM, Newsom-Davis J: The Lambert-Eaton myasthenic syndrome: a review of 50 cases. Brain 111: 577-596, 1988

16）Titulaer MJ, Wirtz PW, Kuks JB, Schelhaas HJ, van der Kooi AJ, et al: The Lambert-Eaton myasthenic syndrome 1988-2008: a clinical picture in 97 patients. J Neuroimmunol 201-202: 153-158, 2008

17）Liu Y, Xi J, Zhou L, Wu H, Yue D, et al: Clinical characteristics and long term follow-up of Lambert-Eaton myasthenia syndrome in patients with and without small cell lung cancer. J Clin Neurosci 65: 41-45, 2019

18）Houzen H, Hattori Y, Kanno M, Kikuchi S, Motomura M, et al: Functional evaluation of inhibition of autonomic transmitter release by autoantibody from Lambert-Eaton myasthenic syndrome. Ann Neurol 43: 677-680, 1998

19）Clouston PD, Saper CB, Arbizu T, Johnston I, Posner JB, et al: Paraneoplastic cerebellar degeneration. III. Cerebellar degeneration, cancer, and the Lambert-Eaton myasthenic syndrome. Neurology 42: 1944-1950, 1992

20）日本神経学会（監修）, 重症筋無力症／ランバート・イートン筋無力症候群診療ガイドライン作成委員会（編）: 重症筋無力症／ランバート・イートン筋無力症候群診療ガイドライン2022. 南江堂, 東京, 2022

21）Nakao YK, Motomura M, Suenaga A, Nakamura T, Yoshimura T, et al: Specificity of omega-conotoxin MVIIC-binding and -blocking calcium channel antibodies in Lambert-Eaton myasthenia syndrome. J Neurol 246: 38-44, 1999

22）Maddison P, Lang B, Mills K, Newsom-Davis J: Longitudinal analysis of serum calcium channel autoantibodies and disease severity in the Lambert-Eaton myasthenic syndrome. J Neurol 145: 382, 1998

23）Graus F, Lang B, Pozo-Rosich P, Saiz A, Casamitjana R, et al: P/Q type calcium channel antibodies in paraneoplastic cerebellar degeneration with lang cancer. Neurology 59: 764-766, 2002

24）Mason WP, Graus F, Lang B, Honnorat J, Delattre JY, et al: Small -cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain 120: 1279-1300, 1997

25）Lorenzoni P, Scola RH, Lang B, Kay CS, Teive HA, et al: Cerebellar ataxia in non-paraneoplastic Lambert-Eaton myasthenic syndrome. J Neurol Sci 270: 194-196, 2008

26）Chalk CH, Murray NM, Newsom-Davis J, O'Neill JH, Spiro SG: Response of the Lambert Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology 40: 1552-1556, 1990

27）Titulaer MJ, Lang B, Verschuuren JJ: Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol 10: 1098-1107, 2011

28）Dau PC, Denys EH: Plasmapheresis and immunosuppressive drug therapy in the Eaton-Lambert syndrome. Ann Neurol 11: 570-575, 1982